Biogen Inc. (NASDAQ:BIIB) Stifel 2024 Virtual CNS Days Conference March 19, 2024 10:00 AM ET Company Participants Priya Singhal - Head of Development & Interim Chief Medical Officer Conference Call Participants Paul Matteis - Stifel Operator Paul Matteis Great. Thank you. Good morning, everybody. It's my pleasure to be hosting this panel with Priya Singhal, Head of Development; and now also Interim Chief Medical Officer at Biogen. Priya has done this panel with me a couple of years in a row, and there's alw ...

Biogen Inc. (NASDAQ:BIIB) Stifel 2024 Virtual CNS Days Conference March 19, 2024 10:00 AM ET Company Participants Priya Singhal - Head of Development & Interim Chief Medical Officer Conference Call Participants Paul Matteis - Stifel Operator Paul Matteis Great. Thank you. Good morning, everybody. It's my pleasure to be hosting this panel with Priya Singhal, Head of Development; and now also Interim Chief Medical Officer at Biogen. Priya has done this panel with me a couple of years in a row, and there's alw ...

In the latest market close, Biogen Inc. (BIIB) reached $219.40, with a +0.04% movement compared to the previous day. The stock's performance was behind the S&P 500's daily gain of 0.63%. Meanwhile, the Dow gained 0.2%, and the Nasdaq, a tech-heavy index, added 0.82%.The company's shares have seen an increase of 0.1% over the last month, not keeping up with the Medical sector's gain of 0.91% and the S&P 500's gain of 1.76%.Investors will be eagerly watching for the performance of Biogen Inc. in its upcoming ...

It has been about a month since the last earnings report for Biogen Inc. (BIIB) . Shares have added about 2.6% in that time frame, underperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Biogen Inc. due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Q4 Earnings & Sales Miss EstimatesBiogen’s fo ...

In the latest market close, Biogen Inc. (BIIB) reached $227.36, with a -1.18% movement compared to the previous day. This move lagged the S&P 500's daily gain of 1.12%. Meanwhile, the Dow experienced a rise of 0.61%, and the technology-dominated Nasdaq saw an increase of 1.54%.The company's stock has dropped by 5.99% in the past month, falling short of the Medical sector's gain of 2.49% and the S&P 500's gain of 2.06%.Investors will be eagerly watching for the performance of Biogen Inc. in its upcoming earn ...

New data from the RESPOND study show that neurofilament levels, an indicator of neurodegeneration, were reduced in nearly all study participants treated with SPINRAZAReductions in biomarker complement previously reported RESPOND efficacy results showing improved motor function in most participants treated with SPINRAZA after gene therapy CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) announced interim 6-month biomarker data from the initial 29 participants in the open-label R ...

New data advances understanding of new approaches to treating Alzheimer's diseaseResearch on disease progression could help inform future clinical trials CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) announced it will present new data from its Alzheimer's disease (AD) portfolio at the upcoming International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2024), taking place March 5-9 in Lisbon, Portugal and virtually. The presentations include new data for its ora ...

If you’re looking for biotech stocks to buy, the iShares Biotechnology ETF (NASDAQ:IBB) is an excellent place to start. It tracks the performance of the ICE Biotechnology Index, a collection of U.S. companies in the biotech industry.  But that exchange traded fund (ETF) hasn’t done well in recent years. In the past three years, its total return was 0.95% in 2021, -13.69% in 2022 and 3.76% in 2023. Year-to-date (YTD), it’s up 2.91%, considerably less than the 8.74% for the SPDR S&P 500 ETF Trust (NYSEARCA:SP ...

Biogen Inc. (NASDAQ:BIIB) TD Cowen 44th Annual Health Care Conference Call March 4, 2024 11:10 AM ET Company Participants Michael McDonnell - Chief Financial Officer Alisha Alaimo - President, Head of North America Priya Singhal - Head of Development and Interim Chief Medical Officer Conference Call Participants Philip Nadeau - TD Cowen Michael McDonnell [Call Starts Abruptly] So good morning and thank you very much to everyone for being with us today. I would say that the launch of LEQEMBI is going in line ...

Biogen Inc. (NASDAQ:BIIB) TD Cowen 44th Annual Health Care Conference Call March 4, 2024 11:10 AM ET Company Participants Michael McDonnell - Chief Financial Officer Alisha Alaimo - President, Head of North America Priya Singhal - Head of Development and Interim Chief Medical Officer Conference Call Participants Philip Nadeau - TD Cowen Michael McDonnell [Call Starts Abruptly] So good morning and thank you very much to everyone for being with us today. I would say that the launch of LEQEMBI is going in line ...